“Our next big focus is the convergence of AI diagnostics, portable imaging & personalized screening”
Koji Wada has been leading Fujifilm’s operations and strategy in India since June 2021, driving growth and profitability through an integrated approach to sales, marketing, and business policies. With over two decades of experience, he has accelerated the company’s expansion in India, introducing several state-of-the-art products and services across verticals. Associated with Fujifilm since 2001, Wada has held key leadership roles in Japan, Myanmar, Thailand, and India.
In an exclusive interaction, Koji Wada, Managing Director, FUJIFILM India shared insights into the company’s key growth drivers, technology trends, business growth and future outlook.
Over the years, FUJIFILM has seen steady growth in imaging technologies. What is driving your year-on-year expansion in India’s CT, MRI, and X-ray market?
Our growth in CT, MRI, and X-ray is powered by continuous innovation and a strong understanding of India’s healthcare needs. We focus on technologies that deliver precision, patient comfort, and clinical efficiency. With public and private healthcare expanding rapidly, we have aligned with this momentum through localized service, training, and application support. We have strengthened our footprint through collaborations with leading hospitals, diagnostic chains, and government healthcare bodies, ensuring greater accessibility to our systems across regions. As the country shifts toward preventive screening, our solutions play a critical role in enabling early and accurate diagnosis, supporting national health priorities.
How do you see the AI-driven advancements in endoscopy, radiology, and digital imaging changing the game in preventive and precision medicine?
AI-driven advancements in endoscopy, radiology, and digital imaging are fundamentally reshaping how we approach preventive and precision medicine. In radiology, AI-powered tools can detect even subtle abnormalities, often at an earlier stage than the human eye, which is especially critical for conditions like cancer and cardiovascular disease, where timely intervention can save lives. For countries like India, where specialist availability is limited, AI can help bridge the gap by assisting general practitioners and technicians with image interpretation, particularly in tier 2 and tier 3 cities. It is also becoming integral to large-scale screening programs for diseases such as breast cancer, tuberculosis, and liver disorders, enabling quick triaging of high volumes of scans for population-level interventions.
In endoscopy, AI is revolutionizing diagnostic accuracy and therapeutic decision-making. From boosting adenoma detection rates and lesion characterization in colonoscopy and assisting early cancer detection in the gastrointestinal tract, AI-assisted systems are increasing precision, minimizing fatigue, and supporting clinicians for better patient care. Advanced computer-assisted diagnosis (CADx) systems are now capable of predicting lesion pathology and identifying infections like Helicobacter pylori, while also supporting personalized treatment planning in complex conditions such as inflammatory bowel disease.
“Fujifilm is leveraging AI to bring a step-change in clinical accuracy, diagnostic speed, and workflow efficiency across imaging modalities.”
How is FUJIFILM leveraging AI to deliver clinical accuracy and speed? What clinical challenges does ENDOVEDA, your AI-assisted endoscopy reporting platform, address and how is it being adopted across India?
Fujifilm is leveraging AI to bring a step-change in clinical accuracy, diagnostic speed, and workflow efficiency across imaging modalities. Our AI-powered platforms, such as ReiLI® and Synapse® AI, are designed to assist gastroenterologist and pulmonologist by detecting key clinical findings like tumors, lesions, or hemorrhages with high precision. Acting as a second set of eyes, these tools enhance diagnostic confidence, reduce variability, and help clinicians make faster, more informed decisions. Importantly, we focus on clinically validated and ethically deployed AI that complements human expertise rather than replacing it, a principle that guides our innovation roadmap.
While Endoveda
is not an AI-assisted solution, it addresses a different but equally critical challenge, standardizing and streamlining endoscopy reporting. By providing a structured, comprehensive reporting interface, Endoveda ensures consistency in documentation, improves workflow efficiency, and reduces the time clinicians spend on manual reporting. It is being rapidly adopted by hospitals and gastroenterology clinics across India for its ability to integrate seamlessly into existing workflows, enhance data accuracy, and support better clinical record-keeping, ultimately contributing to improved continuity of care.
Given the government’s thrust on ‘Make in India’, do you plan to localize R&D and manufacturing capabilities?
“Make in India” is definitely a part of the expansion strategy of FUJIFILM India and currently various business divisions are studying this topic and making their business plan to achieve long-term objective of the company which is to contribute to a world filled with more smiles. You will hear from us soon, on the front of “Make in India” where we will be taking small steps of progress in establishing our manufacturing footprint in India.
Could you elaborate on FUJIFILM’s collaborative initiatives in areas like breast cancer awareness and TB eradication, and how they reflect scalable, high-impact healthcare delivery models?
Since 2021, we were actively involved in the government’s aim to eliminate TB and were able to cover the remotest corners of the country. It started with our Never Stop campaign and continued with our CSR initiatives “Where Innovation Meets Care” joined with “100 Days to TB Elimination campaign” and with all our efforts we were able to screen 125,093 individuals for TB using Ultra-Portable Handheld FDR X-Air in 15 states of India where 1,161 people were detected with TB.
We are now gradually transitioning our focus to Women Health and Advocacy wherein through our CSR Campaign “Find It Early. Fight It Early,” we have aimed to reach more than 200,000 women through Health Risk Assessment where 3000 individuals will be supported with handholding and referral assistance for follow-up diagnostics and care through our medical marketing campaign. The process flow includes – raising awareness and sensitization through Camps in different communities, doing HRA and then referring them for screening.
The program aims to raise awareness about the significance of Breast cancer screening and the associated risk factors. The initiative will educate communities, provide accessible healthcare resources, and empower individuals to take charge of their health. Last year with our Breast Cancer Awareness and Screening campaign we could reach out to 1,01,639 women mostly from the underserved community with 1500 mammography screening making technology more inclusive and pursue women to take a charge of their own health.
“Over the past 3–5 years, FUJIFILM India’s Medical Systems Division has maintained a robust double-digit growth trajectory.”
What has been the trajectory of the company’s healthcare revenue growth trajectory over the past 3–5 years, particularly in high-impact segments such as CT, MRI, and X-ray?
Over the past 3–5 years, FUJIFILM India’s Medical Systems Division has maintained a robust double-digit growth trajectory, powered by our focus on technology innovation, customer trust, and strategic expansion in high-impact imaging segments such as CT, MRI, and X-ray.
CT and MRI systems have emerged as major growth drivers, particularly in tertiary care hospitals and advanced diagnostic centers. Our premium and mid-range systems are gaining rapid adoption for their clinical accuracy, compact design, and cost-efficiency tailored to Indian healthcare needs. In digital radiography, Fujifilm has established market leadership with our Portable X-ray Unit FDR Xair, which are being deployed extensively in both urban and rural setups.
We have seen strong uptake in government tenders and public–private partnership models, especially for DR and mobile X-ray units supporting national screening programs for TB and non-communicable diseases. Growth has also been fueled by the localization of our service and support infrastructure, strategic collaborations with healthcare chains and diagnostic partners, the launch of AI-powered solutions across modalities, and focused investments in training and clinician engagement. Looking ahead, our next big bet is on integrating AI diagnostics, portable imaging, and personalized screening to create scalable, value-based care models for India.
Where is the next big bet for FUJIFILM India, AI diagnostics, portable imaging, personalized screening, or something else entirely?
Our next big bet is on the convergence of AI diagnostics, portable imaging, and personalized screening. By combining these, we are creating an integrated ecosystem that ensures timely, accurate, and accessible care. Whether it’s an FDR X-Air enabling on-the-spot screening in remote villages or AI helping clinicians detect disease earlier, our goal is clear—early detection, faster decisions, and better outcomes across every corner of India.
*This interview was first published in the September 2025 edition of BioVoice eMagazine.
The post “Our next big focus is the convergence of AI diagnostics, portable imaging & personalized screening” appeared first on BioVoiceNews.
News